CLOs on the Move

Genocea

www.genocea.com

 
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.genocea.com
  • 100 Acorn Park Drive
    Cambridge, MA USA 02140
  • Phone: 617.876.8191

Executives

Name Title Contact Details
Jacquelyn Sumer
Chief Legal and Compliance Officer Profile
Derek Meisner
Senior Vice President and General Counsel Profile
Derek Meisner
Senior Vice President and General Counsel Profile

Similar Companies

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

Nuvelo

Nuvelo, Inc. is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Q Therapeutics

Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AltheaDx

AltheaDx, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. AltheaDx, Inc. is based in San Diego, CA. You can find more information on AltheaDx, Inc. at www.altheadx.com

Rakuten Medical

Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company`s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has 6 locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland.